





- Smoking
- Getting up too early for HD

Novak M et al. Sem Dial 2006;19:25-31




Return when sleepy Novak M et al. Sem Dial 2006;19:25-31 http://phc.eduhealth.ca/PHC_PDFs/FM/FM.900.St82.PHC.pdf ;




Benz	zodio	azepi	nes	
	Half life (hr)	Dose	Adverse Effects	Drug Interactions
Short – for ear	ly insomnia – c	onset 15-30 min **	NOT recommended **	
Triazolam	2-5	0.125-0.25 mg	Amnesia, rebound Drowsiness, dizziness, incoordination	No active metabolite Metabolized by CYP 3A4
Intermediate ·	- for sleep-ma	intenance insomr	ia – onset 1-2 hrs	
Lorazepam	10-20	0.5-2 mg	Amnesia, drowsiness, dizziness,	No active metabolite Glucuronidation
Oxazepam	5-20	10-30 mg	incoordination	No active metabolite Glucuronidation
Temazepam	9.5-12	15-30 mg		No active metabolite Glucuronidation
Long - ** NO	recommende	ed **		
Diazepam	20-50	2-5 mg	Amnesia, drowsiness, dizziness.	Active metabolites;
Flurazepam	40-114	15-30 mg	incoordination	Active metabolites; CYP 3A4/2D6


		Degleger and an interaction	
Non-ber	nzodiazepir	ne GABA ag	gonists
	Zopiclone	Zolpidem	Zaleplon*
Onset	30-60 min	30 min	15-30 min
Duration	5-8 hrs	6-8 hrs	2-4 hrs
Elimination t _{1/2}	~5 hrs	2.5-3 hrs	1 hr
Indications	Early and middle insomnia	Early and middle insomnia	Early insomnia
Dosing	5-10mg	10mg (If ≤ 4 hr sleep left 1.75mg♀;3.5mg ೆ)	7.5-15 mg
Dosing in Elderly	3.75-5mg	5mg*	5 mg
Metabolism	CYP 3A4	CYP 3A4	Aldehyde oxidase
*available in US only	/	Bain KT Am J Geriatr Pharmacot	her 2006;4:168-92








Adverse effects: weight gain, anticholinergic effects














Medication causes of insomnia				
 Recreational Drugs 	 Neurologic and 			
Alcohol	psychotropic agents			
Caffeine	Levodopa			
Nicotine	Phenytoin			
Amphetamines and	Lamotrigine			
Methamphetamines	Bupropion			
Drug withdrawal	SSRI, e.g. fluoxetine			
 Cardiovascular agents 	SNRI, e.g. venlafaxine			
Diuretics	 Miscellaneous agents 			
Beta blockers	Theophylline			
Endocrine agents	Oral Contraceptives			
Corticosteroids	Cimetidine			
Thyroid hormone	Pseudoephedrine			
Stimulants	Stimulant Laxatives			
Methylphenidate	Interferon			
Dextroamphetamine	Donepezil			






Assessment Rule out mimic disorders Rule out drug-induced RLS Assess risk/contributing factors Iron deficiency Sleep deprivation Positive family history Beenmandi arthritis or Siongran's	Mimic Conditions Movement disorders: akathisia, ADHD Restlessness secondary to anxiety, depression, psychotic disorders Local leg pathology: e.g. peripheral neuropathy, myelopathy, peripheral venous congestion Positional discomfort
 Rheumatoid arthritis or Sjogren's Pregnancy 	Drug-induced RLS
Initial Recommendation Discontinue or reduce offending drug, if feasible Correct fron deficiency - may prevent initial augmentation with dopaminergic therapy Encourage good sleep hygiene (see insomnia flowchart) http://phc.eduheatih.ca/PHC.PDFs/FM/FM.700.5182.PHC.pdf	 Dopamine antagonists: Antipsychotics: primozide, haloperidol, olanzapine, risperidone Metoclopramide, promethazine Antidepressants: Mirtazapine (up to 28%) SSRI (5%) e.g. citalopram, escitalopram, fluoxetine,
Medication options +Avoid opioids and quinine +For intermittent RLS: Levodopa/carbidopa +For daily RLS; dopamine agonist +For RLS with painful neuropathy: gabapentin	paroxetine, sertraline SIRI's (=5%), e.g. duloxetine, ventafaxine Stimulants: alcohol, caffeine, nicotine Others: TCA's, carbamazepine, lithium
Refractory Symptoms •Clonazepam •Clonidine	nable efficacy and adverse effects due to clonaxepam's bro. f 2 mg po HS 23








Consequences Decreased Quality of life Insomnia 70% complained of insomnia due to itch with score ≥ 7 Mood disorders Increased mortality associated with high itch score
















Evidence	or lack	0	f
Treatment	Study Type	n	Response
Emollient	Open noncontrolled	21	Remission in 9
Capsaicin 0.025% cr TID x 2wks 0.03% oint QID x 4wks	DB, x-over R,DB,PC,x-over	19 34	Remission in 5; ↓ in 9 ↓84% in pruritus score
γ-linolenic acid 2.2% cr	R,DB,PC, x-over	16	↓40% in pruritus score
Gabapentin 300mg post HD 400mg twice/wk 100mg post HD	R,DB,PC,x-over R,DB,PC,x-over DB,PC,x-over	25 34 25	
Pregabalin 25mg po HS	Open, noncontrolled	12	↓77% in VAS
Activated charcoal 6g/day x 8 wks	PC, x-over	11 23	↓33% in pruritus score Remission in 10, ↓ in 10
Cholestyramine 5g bid	PC, DB	10	↓47% in pruritus score in 4 treated


















Opioids	Comments		
Mild Pain			
codeine	~10% pts lack the enzyme to convert codeine to morphine. May cause more nausea & constipation than other narcotics		
Moderate Severe	Pain		
morphine	Active metabolites renally cleared and may accumulate in ESRD. Cautio with chronic use in renal pts		
hydromorphone	Slightly shorter duration than morphine. Less accumulation than morphine in pts with renal failure		
oxycodone	Limited data in renal dysfunction – caution		
fentanyl	Causes less nausea or histamine release Transdermal patch is not recommended for acute pain or narcolic naïve pits; patch may last up to 72 hrs but small # of pts may require q48hr dosing		
methadone	Accumulates with repeated dosing, esp on days 2-5. Variable half-life (17-128hrs), longer to titrate. Use with caution in elderly. Blocks NMDA receptor; slow development of tolerance.		
Meperidine	Not recommended for post-op or chronic pain management. Neurotoxic and seizure risk. Metabolites accumulate in renal dysfunction.		
	Ferro CJ et al. Management of pain in renal failu In: Supportive Care for the Renal Patient. EJ Chambers: M Germain: EA Brown de Davisors NJ. Patiente Med 2007/10/1277		


Opioids	SPEE LIMI 5	
Adverse Effects	Management	
CNS		
Sedation/dizziness	Slow titration; Not to drive	
Myoclonus	↓ Dose or Switch to hydromorphone	
Confusion/delirium	↓ Dose or Switch to hydromorphone	
CVS		
Hypotension/bradycardia	↓ Dose; atropine	
Resp	ł	
Respiratory depression	↓ Dose; naloxone	
GI	1	
Nausea/vomiting	Antiemetics	
Constipation	Fluid; exercise; bulking agent; stool softener; stimulant	
Pruritus	Switch opioids; antihistamines	



Iricyc	lic Ar	itidep	pressa	nts
Side Effects	Amitriptyline (Elavil®)	Imipramine (Tofranil®)	Nortriptyline (Aventyl®)	Desipramine (Norpramin®)
Sedation	++++	+++	+	+/-
Confusion	++++	+++	+	+
Orthostatic Hypotension	+++	+++	+	++
Arrhythmia	++	++	++	++
Anticholinergic	++++	+++	++	+
Weight Gain	++++	+++	++	++

Anticonv	ulsants	
Gabapentin firstAdverse effects	st line s: Somnolence, dizz	iness, ataxia
	gabapentin	pregabalin
Absorption	Saturable	Non-saturable across dose range
Oral bioavailability	60% 900mg 47% 1200mg 34% 2400mg 33% 3600mg	≥ 90%
Renal Elimination	70-80%	90-99%
Renal Impairment	Dosage adjustment	Dosage adjustment
Dialyzability	Yes	Yes
Onset of action	≥9 days	1-3 days





• Start with 0.5mg PO HS

